The levels of IL-5 (Fig. 3A), IP-10 (Fig. 3B), and soluble FAS-L (Fig. 3C) were significantly increased in the sera of patients with dermatitis, at 7 to 30 days after the initiation of treatment, but not in subjects without dermatitis or uninfected subjects. This evidence concerns the gene FASLG and dermatitis.